Perioperative management of antiplatelet therapy in patients with drug-eluting stents.

Clopidogrel IBS Patients Have Higher Incidence of Gastrointestinal Symptoms Influenced by Age and Gender. Dig Dis Sci (2017) 0.75

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81

A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med (1994) 9.15

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54

A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med (1994) 7.96

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol (2006) 6.07

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 5.94

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37

Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation (2007) 5.05

Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68

Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med (2001) 3.85

Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation (1995) 3.82

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45

Bare metal stent restenosis is not a benign clinical entity. Am Heart J (2006) 3.39

Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation (2007) 3.34

ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation (2007) 3.25

Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation (2003) 3.22

Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol (2003) 3.13

Coronary artery stenting and non-cardiac surgery--a prospective outcome study. Br J Anaesth (2006) 3.08

Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA (2005) 3.06

Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol (2000) 3.01

Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med (2005) 2.98

Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation (2007) 2.93

Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 2.90

The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol (2004) 2.78

TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation (2003) 2.74

Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA (2007) 2.49

Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA (2007) 2.43

Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation (2009) 2.40

A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J (2006) 2.22

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation (2011) 1.99

Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest (2004) 1.87

Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation (2003) 1.76

Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv (2004) 1.76

Drug-eluting stents: cost versus clinical benefit. Circulation (2003) 1.70

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation (2010) 1.69

Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery (1994) 1.66

Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth (2007) 1.63

"Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol (2008) 1.61

Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol (2006) 1.52

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA (2012) 1.43

Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation (2004) 1.42

Late thrombosis of a drug-eluting stent presenting in the perioperative period. Anesthesiology (2007) 1.37

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation (1998) 1.37

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2011) 1.33

Coronary artery stents: Part I. Evolution of percutaneous coronary intervention. Anesth Analg (2008) 1.32

Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31

Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg (2002) 1.30

Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol (2006) 1.30

Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest (2006) 1.25

Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J (2000) 1.23

Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.20

Coronary artery stents: II. Perioperative considerations and management. Anesth Analg (2008) 1.20

Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg (2011) 1.09

The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am Heart J (1995) 1.09

Drug-eluting stents. Annu Rev Med (2004) 1.09

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J (2010) 1.07

Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol (2007) 1.06

Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol (2007) 0.99

How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. Clin Res Cardiol (2008) 0.99

Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol (2005) 0.98

Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation (2011) 0.95

New frontiers in cardiology: drug-eluting stents: Part II. Circulation (2003) 0.94

A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. J Am Coll Cardiol (2002) 0.92

Combined aspirin and clopidogrel in cataract surgical patients: a new risk factor for ocular haemorrhage? Br J Ophthalmol (2004) 0.90

Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost (2011) 0.89

Aspirin and post-prostatectomy haemorrhage. Br J Urol (1993) 0.87

Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypass. Anesth Analg (2004) 0.87

Anaesthetic considerations in a parturient with critical coronary artery disease and a drug-eluting stent presenting for caesarean section. Int J Obstet Anesth (2005) 0.86

Percutaneous coronary intervention: historical perspectives, current status, and future directions. Am Heart J (2003) 0.83

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol (2001) 0.83

Granulomatous 'foreign body reactions' contribute to exaggerated in-stent restenosis. Coron Artery Dis (1999) 0.79

Perioperative management of patients with drug-eluting stents. JACC Cardiovasc Interv (2010) 0.79

Contemporary approaches to perioperative management of coronary stents and to preoperative coronary revascularization: a survey of 374 interventional cardiologists. Cardiovasc Revasc Med (2010) 0.78

Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. Neth Heart J (2007) 0.78

Thrombosis of sirolimus-eluting coronary stent in the postanesthesia care unit. Anesth Analg (2005) 0.78

Perioperative hemorrhage and combined clopidogrel and aspirin therapy. Anesthesiology (2004) 0.77

Outcome of non-cardiac surgery after stent implantation in the DES era: results of the Surgery After Stent (SAS) registry. J Invasive Cardiol (2011) 0.76

Anaesthesia in patients with drug-eluting stents. Curr Opin Anaesthesiol (2008) 0.76

Appropriate waiting time for noncardiac surgery following coronary stent insertion: views of Canadian anesthesiologists [corrected]. Can J Anaesth (2005) 0.76

Pre-injury neuro-psychiatric medication use, alone or in combination with cardiac medications, may affect outcomes in trauma patients. J Postgrad Med (2014) 2.16

Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody. Transplantation (1996) 0.95

Prolonged murine cardiac allograft acceptance: characteristics of persistent active alloimmunity after treatment with gallium nitrate versus anti-CD4 monoclonal antibody. Transplantation (1997) 0.81

Patterns of inflammatory vascular endothelial changes in murine liver grafts. Transplantation (1995) 0.78

Immunologic characterization of murine cardiac allograft recipients with long-term graft survival due to anti-VCAM-1 or anti-CD4 monoclonal antibody therapy. Transplant Proc (1995) 0.77

Gene therapy in transplantation: pathological consequences of unavoidable plasmid contamination with lipopolysaccharide. Transpl Immunol (1999) 0.76

Author's reply: To PMID 25370543. J Postgrad Med (2015) 0.75

Author's reply: To PMID 25370543. J Postgrad Med (2015) 0.75

Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling. J Heart Lung Transplant (1997) 0.75